Evidence map›Paper›PMID 7966566›Full record

ArticleJournal of virology1994

Comparison of mucosal and systemic humoral immune responses and subsequent protection in mice orally inoculated with a homologous or a heterologous rotavirus.

N Feng, J W Burns, L Bracy, H B Greenberg

Erratum issued Registry-linked trialOpen access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of virology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03602053 (An Open-label, Randomized, Controlled, Single Centre, Phase IIb Study to Assess the Immunogenicity, Reactogenicity and Safety of Three Live Oral Rotavirus Vaccines, ROTAVAC® , ROTAVAC 5CM and Rotarix® in Healthy Zambian Infants), which is not on this map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03602053 phase2 / phase3completednot on this mapstarted 2019, after this paper: background citation

An Open-label, Randomized, Controlled, Single Centre, Phase IIb Study to Assess the Immunogenicity, Reactogenicity and Safety of Three Live Oral Rotavirus Vaccines, ROTAVAC® , ROTAVAC 5CM and Rotarix® in Healthy Zambian Infants

TypeinterventionalSponsorCentre for Infectious Disease Research in ZambiaRan2019 to 2019Enrolled450ConditionsDiarrhea, Diarrhea RotavirusArmsROTAVAC®, ROTAVAC 5D, Rotarix®
3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 194 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Mucosal and systemic neutralizing antibodies to norovirus induced in infant mice orally inoculated with recombinant rotaviruses.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  11. Review
  12. Review
  13. LAPJournal of virology · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

N FengDepartment of Medicine, Microbiology and Immunology, Stanford University School of Medicine, California 94305.
J W Burns
L Bracy
H B Greenberg
Stanford University · US

Funding

GASTROINTESTINAL MEMBRANE RECEPTORSP30DK038707 · NIDDK · STANFORD UNIVERSITY · PI GRAY, GARY M. · 1987 to 1997
–
NIAID NIH HHS R01AI21632NIDDK NIH HHS DK38707
6 · The paper itself

Abstract

Rotaviruses are the single most important cause of severe diarrhea in young children worldwide, and vaccination is probably the most effective way to control the disease. Most current live virus vaccine candidates are based on the host range-restricted attenuation of heterologous animal rotaviruses in humans. The protective efficacy of these vaccine candidates has been variable. To better understand the nature of the heterologous rotavirus-induced active immune response, we compared the differences in the mucosal and systemic immune responses generated by heterologous (nonmurine) and homologous (murine) rotaviruses as well as the ability of these infections to produce subsequent protective immunity in a mouse model. Sucking mice were orally inoculated with a heterologous simian or bovine rotavirus (strain RRV or NCDV) or a homologous murine rotavirus (wild-type or tissue culture-adapted) strain EHP at various doses. Six weeks later, mice were challenged with a virulent murine rotavirus (wild-type strain ECW) and the shedding of viral antigen in feces was quantitated. Levels of rotavirus-specific serum immunoglobulin G (IgG) and fecal IgA prior to challenge were measured and correlated with subsequent viral shedding or protection. Heterologous rotavirus-induced active protection was highly dependent on the strain and dose of the virus tested. Mice inoculated with a high dose (10(7) PFU per mouse) of RRV were completely protected, while the protection was diminished in animals inoculated with NCDV or lower doses of RRV. The ability of a heterologous rotavirus to stimulate a detectable intestinal IgA response correlated with the ability of the virus to generate protective immunity. Serum IgG titer did not correlate with protection. Homologous rotavirus infection, on the other hand, was much more efficient at inducing both mucosal and systemic immune responses as well as protection regardless of the virulence of the virus strain or the size of the immunizing dose.

Indexed as

Administration, OralAnimalsAnimals, SucklingAntibodies, ViralAntibody FormationAntigens, ViralCattleEnzyme-Linked Immunosorbent AssayFemaleHaplorhiniImmunoglobulin AImmunoglobulin GIntestinal MucosaMiceMice, Inbred BALB CPregnancyAntibodies, ViralAntigens, ViralImmunoglobulin AImmunoglobulin GViral Vaccines

Identifiers

PMID7966566
PMCPMC237238
OpenAlexW1623873373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.